Zolbetuximab

From WikiProjectMed
(Redirected from IMAB362)
Jump to navigation Jump to search
Zolbetuximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric
TargetCLDN18.2
Clinical data
Other namesIMAB362; Claudiximab
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Zolbetuximab (development code IMAB362) is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.[1]

The drug is in phase III clinical trials as of November 2021.[2]

Preliminary results from the phase II 'FAST' trial in June 2016 suggest it is helpful for advanced gastric cancer.[3]

References

  1. ^ "Our mission - Ganymed Pharmaceuticals GmbH - Ganymed Pharmaceuticals GmbH". www.ganymed-pharmaceuticals.de.
  2. ^ "A Study of Zolbetuximab (IMAB362)". clinicaltrials.gov. 19 November 2021.
  3. ^ "Antibody Shines in Advanced Gastric Cancer". medpagetoday.com. 5 June 2016.